Comprehensive Analysis of the Immune Cell Infiltration Landscape and Immune-Related Methylation in Retinoblastoma.
DNA methylation
bioinformatics analysis
immune cell infiltration
immunotherapy
retinoblastoma
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
01
2022
accepted:
21
03
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Retinoblastoma is a common pediatric intraocular cancer, originating from cone precursors. The development of immunotherapies can help eradicate the tumor without vision loss, which would largely improve the quality of life of patients with retinoblastoma. Investigation of the tumor immune microenvironment provides knowledge for developing novel immunotherapies in cancer. However, the immune cell infiltrative landscape of retinoblastoma is unknown. Here, we compared the relative expression of immune gene signatures among 59 patients with retinoblastoma. The patients were divided into two subgroups according to the 28 types of immune cell infiltration (ICI) scores. We found that a subgroup with high ICI scores had increased expression levels of late cone markers, while the other subgroup exhibited larger tumor size and metastasis propensity. Furthermore, hypermethylated genes in the high-ICI subgroup were associated with immune regulation in the tumor microenvironment, suggesting that DNA methylation may play a vital regulatory role in retinoblastoma immunity. Our study provides a comprehensive framework for the systemic analysis of the influences of epigenetic events on the tumor immune microenvironment. We anticipate that our assay can not only provide insights into tumor immune regulation but also open up the perspectives for the identification of novel immunotherapy targets for retinoblastoma.
Identifiants
pubmed: 35664300
doi: 10.3389/fgene.2022.864473
pii: 864473
pmc: PMC9157546
doi:
Types de publication
Journal Article
Langues
eng
Pagination
864473Informations de copyright
Copyright © 2022 Mao, Shen, Xu and Zhong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Genome Med. 2014 Aug 30;6(8):66
pubmed: 25473433
Clin Epigenetics. 2019 Nov 14;11(1):159
pubmed: 31727122
Cell Death Dis. 2010;1:e8
pubmed: 21364627
Neuropsychopharmacology. 2013 Jan;38(1):23-38
pubmed: 22781841
Br J Ophthalmol. 2019 Sep;103(9):1272-1277
pubmed: 30361279
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Ophthalmology. 2006 Sep;113(9):1558-66
pubmed: 16828510
BMC Genomics. 2015 Feb 05;16:49
pubmed: 25652663
Nat Commun. 2017 Nov 9;8(1):1379
pubmed: 29123100
Medicine (Baltimore). 2020 Nov 20;99(47):e23314
pubmed: 33217867
Nat Cancer. 2020 Oct;1(10):990-997
pubmed: 33898999
Nat Rev Genet. 2016 May;17(5):284-99
pubmed: 26972587
Genome Biol. 2014;15(8):435
pubmed: 25146004
BMC Syst Biol. 2014;8 Suppl 4:S11
pubmed: 25521941
Nat Commun. 2018 Dec 18;9(1):5361
pubmed: 30560866
Nat Rev Dis Primers. 2015 Aug 27;1:15021
pubmed: 27189421
Clin Epigenetics. 2019 Dec 3;11(1):178
pubmed: 31796082
Nat Commun. 2017 Dec 11;8(1):2032
pubmed: 29230012
Fac Rev. 2021 May 28;10:51
pubmed: 34195690
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Front Genet. 2021 Feb 11;12:625236
pubmed: 33643387
PLoS One. 2016 Apr 06;11(4):e0153011
pubmed: 27050416
Nat Commun. 2021 Jul 27;12(1):4535
pubmed: 34315877
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
BMC Biol. 2021 May 25;19(1):107
pubmed: 34030676
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Epigenomics. 2009 Dec;1(2):239-59
pubmed: 20495664
Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97
pubmed: 32368178
Nat Rev Genet. 2021 Apr;22(4):235-250
pubmed: 33244170
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Front Oncol. 2021 Feb 02;10:606735
pubmed: 33604289
JAMA Ophthalmol. 2015 Nov;133(11):1341-7
pubmed: 26378747
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Br J Ophthalmol. 2015 Apr;99(4):457-63
pubmed: 25326518
Nat Commun. 2021 Sep 22;12(1):5578
pubmed: 34552068
Cancer Immunol Immunother. 2012 Nov;61(11):2091-103
pubmed: 22565484
Int J Neuropsychopharmacol. 2021 Nov 12;24(11):879-891
pubmed: 34214162
Nat Cancer. 2020 Nov;1(11):1097-1112
pubmed: 34296197
Stem Cell Reports. 2017 Dec 12;9(6):1898-1915
pubmed: 29153988
Trends Mol Med. 2019 Nov;25(11):955-966
pubmed: 31253589
Front Oncol. 2021 Apr 16;11:575425
pubmed: 33937014
J Exp Clin Cancer Res. 2019 Aug 22;38(1):368
pubmed: 31439015
J Transl Med. 2004 Jun 13;2(1):19
pubmed: 15193151
Cancer Res. 1997 Jun 1;57(11):2229-37
pubmed: 9187126
Lab Invest. 2021 Jun;101(6):701-718
pubmed: 33658609
Cancer Immunol Immunother. 2016 Nov;65(11):1339-1352
pubmed: 27576783
Oncogene. 2002 Aug 12;21(35):5427-40
pubmed: 12154405
Nat Commun. 2013;4:2612
pubmed: 24113773
Nat Rev Cancer. 2022 May;22(5):298-313
pubmed: 35236940
J Clin Invest. 2015 Sep;125(9):3335-7
pubmed: 26325031
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Clin Cancer Res. 2018 Aug 1;24(15):3717-3728
pubmed: 29666300
Bioinformatics. 2017 Dec 15;33(24):3982-3984
pubmed: 28961746
Sci Rep. 2017 Sep 18;7(1):11762
pubmed: 28924151
Adv Genet. 2010;70:27-56
pubmed: 20920744